Revelation Biosciences(REVB)
$4.36+0.42 (+10.66%)
REVB
Revelation Biosciences financials statements
$4.36
At close:+0.42 (+10.66%)
Want to see REVB full AI Analyst Report?
Revelation Biosciences (REVB) Ratios
312 Followers
Revelation Biosciences Ratios
REVB's free cash flow for Q3 2026 was $-2.36M. For the 2026 fiscal year, REVB's free cash flow was increased by $0.00 and operating cash flow was $-2.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.89 |
| Quick Ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.89 |
| Cash Ratio | 5.36 | 3.40 | 2.15 | 1.18 | 0.60 |
| Solvency Ratio | -3.26 | -7.84 | -0.02 | -2.43 | -5.59 |
| Operating Cash Flow Ratio | -4.14 | -9.57 | -1.31 | -2.52 | -5.18 |
| Short-Term Operating Cash Flow Coverage | -359.34 | 0.00 | 0.00 | 0.00 | -662.04 |
| Net Current Asset Value | $ 8.09M | $ 4.65M | $ 6.58M | $ 962.32K | $ -229.61K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.08 | 0.00 | 0.00 | 0.00 | -0.17 |
| Debt-to-Capital Ratio | 0.08 | 0.00 | 0.00 | 0.00 | -0.20 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.41 | 1.84 | 5.23 | -20.53 |
| Debt Service Coverage Ratio | -392.98 | 0.00 | 0.00 | 0.00 | -203.96 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -286.18 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 8.42 | 0.00 | 0.00 | 0.00 | 99.58 |
| Net Debt to EBITDA | 1.10 | 0.82 | 1.39 | 0.48 | 0.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.27% | 188.57% | 1.39% | 99.68% | 100.30% |
| Return on Assets (ROA) | -76.96% | -227.10% | -0.98% | -196.78% | -586.95% |
| Return on Equity (ROE) | -100.59% | -319.40% | -1.81% | -1028.98% | 12050.71% |
| Return on Capital Employed (ROCE) | -94.64% | -169.38% | -130.22% | -1032.30% | 12014.16% |
| Return on Invested Capital (ROIC) | -94.41% | -169.38% | -130.22% | -1032.30% | 18116.13% |
| Return on Tangible Assets | -76.96% | -227.10% | -0.98% | -196.78% | -586.95% |
| Earnings Yield | -448.70% | -99.05% | -1.17% | -100.65% | -11.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.04 | 0.02 | 0.07 | 0.12 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -10243.23 | -19815.67 | -5056.11 | -3146.56 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 10243.23 | 19815.67 | 5056.11 | 3146.56 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -93.25 | -106.82 | -509.89 | -9990.56 | -18874.95 |
| Free Cash Flow Per Share | -93.25 | -106.94 | -509.89 | -9990.56 | -19099.53 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -955.68 | 0.00 | 0.00 | -84.04 |
| Capital Expenditure Coverage Ratio | 0.00 | -955.68 | 0.00 | 0.00 | -84.04 |
| Operating Cash Flow Coverage Ratio | -11.07 | 0.00 | 0.00 | 0.00 | -662.04 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -416.28% | -120.80% | -70.72% | -104.27% | -11.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.13 | -1.01 | -342.72 | -3.97 | -33.60 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.22 | 3.22 | 6.20 | 40.89 | -4048.98 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.24 | -0.83 | -5.66 | -3.84 | -35.89 |
| Price-to-Operating Cash Flow Ratio | -0.24 | -0.83 | -5.66 | -3.84 | -36.31 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | 3.43 | 0.08 | -0.27 |
| Enterprise Value Multiple | 0.88 | -1.09 | -3.39 | -3.49 | -33.64 |
| Enterprise Value | -7.97M | 8.68M | -1.69M | 5.51M | 99.43M |
| EV to EBITDA | 0.88 | -1.09 | 0.20 | -0.51 | -8.33 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.96 | -0.47 | 0.23 | -0.49 | -8.86 |
| EV to Operating Cash Flow | 0.96 | -0.47 | 0.23 | -0.49 | -8.97 |
| Tangible Book Value Per Share | 99.91 | 27.45 | 465.20 | 937.18 | -169.29 |
| Shareholders’ Equity Per Share | 99.91 | 27.45 | 465.20 | 937.18 | -169.29 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -100.51 | -87.68 | -8.42 | -9643.41 | -20400.29 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.89 | 0.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.93 | 1.22 | 60.59 | 1.04 | 0.93 |
Currency in USD
